Table of Content

Table of Contents

Global Neoantigen Vaccine Market Segment Research Report 2022
1. Research Scope
2. Market Overview
2.1 Product Introduction, Application, Picture
2.2 Global Neoantigen Vaccine Market by Value
2.2.1 Global Neoantigen Vaccine Revenue by Type
2.2.2 Global Neoantigen Vaccine Market by Value (%)
2.3 Global Neoantigen Vaccine Market by Production
2.3.1 Global Neoantigen Vaccine Production by Type
2.3.2 Global Neoantigen Vaccine Market by Production (%)

3. The Major Driver of Neoantigen Vaccine Industry
3.1 Historical & Forecast Global Neoantigen Vaccine Demand
3.2 Largest Application for Neoantigen Vaccine (2018-2028)
3.3 The Major Downstream Company in China Market 2022

4. Global and Regional Neoantigen Vaccine Market
4.1 Regional Market Size in Terms of Production & Demand (2022)
4.2 Regional Market Share in Terms of Revenue (2018-2022)
4.3 Concentration Ratio (CR5& CR10) of Neoantigen Vaccine Market
4.4 Mergers & Acquisitions, Expansion Plans

5. US Neoantigen Vaccine Production, Revenue (2018-2028)
5.1 Current and Estimated Production Breakdown by Type
5.2 Current and Estimated Production Breakdown by Application
5.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
5.4 Current and Estimated Revenue Breakdown by Application (2018-2028)

6. Europe Neoantigen Vaccine Production, Revenue (2018-2028)
6.1 Current and Estimated Production Breakdown by Type
6.2 Current and Estimated Production Breakdown by Application
6.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
6.4 Current and Estimated Revenue Breakdown by Application (2018-2028)

7. China Neoantigen Vaccine Production, Revenue (2018-2028)
7.1 Current and Estimated Production Breakdown by Type
7.2 Current and Estimated Production Breakdown by Application
7.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
7.4 Current and Estimated Revenue Breakdown by Application (2018-2028)

8. Japan Neoantigen Vaccine Production, Revenue (2018-2028)
8.1 Current and Estimated Production Breakdown by Type
8.2 Current and Estimated Production Breakdown by Application
8.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
8.4 Current and Estimated Revenue Breakdown by Application (2018-2028)

9. India Neoantigen Vaccine Production, Revenue (2018-2028)
9.1 Current and Estimated Production Breakdown by Type
9.2 Current and Estimated Production Breakdown by Application
9.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
9.4 Current and Estimated Revenue Breakdown by Application (2018-2028)

10. Korea Neoantigen Vaccine Production, Revenue (2018-2028)
10.1 Current and Estimated Production Breakdown by Type
10.2 Current and Estimated Production Breakdown by Application
10.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
10.4 Current and Estimated Revenue Breakdown by Application (2018-2028)

11. Southeast Asia Neoantigen Vaccine Production, Revenue (2018-2028)
11.1 Current and Estimated Production Breakdown by Type
11.2 Current and Estimated Production Breakdown by Application
11.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
11.4 Current and Estimated Revenue Breakdown by Application (2018-2028)

12. Global Neoantigen Vaccine Average Price Trend
12.1 Market Price for Each Type of Neoantigen Vaccine in US (2018-2022)
12.2 Market Price for Each Type of Neoantigen Vaccine in Europe (2018-2022)
12.3 Market Price for Each Type of Neoantigen Vaccine in China (2018-2022)
12.4 Market Price for Each Type of Neoantigen Vaccine in Japan (2018-2022)
12.5 Market Price for Each Type of Neoantigen Vaccine in India (2018-2022)
12.6 Market Price for Each Type of Neoantigen Vaccine in Korea (2018-2022)
12.7 Market Price for Each Type of Neoantigen Vaccine in Southeast Asia (2018-2022)

13. Industrial Chain (Impact of COVID-19)
13.1 Neoantigen Vaccine Industrial Chain Analysis
13.2 Downstream
13.3 Impact of COVID-19
13.4 Post-pandemic Era
13.5 Technology Trends of Neoantigen Vaccine

14. Neoantigen Vaccine Competitive Landscape
14.1 Pfizer
14.1.1 Pfizer Company Profiles
14.1.2 Pfizer Product Introduction
14.1.3 Pfizer Neoantigen Vaccine Production, Revenue (2018-2022)
14.1.4 Strategic initiatives
14.2 Merck & Co Inc
14.2.1 Merck & Co Inc Company Profiles
14.2.2 Merck & Co Inc Product Introduction
14.2.3 Merck & Co Inc Neoantigen Vaccine Production, Revenue (2018-2022)
14.2.4 Strategic initiatives
14.3 Eli Lilly and Company
14.3.1 Eli Lilly and Company Company Profiles
14.3.2 Eli Lilly and Company Product Introduction
14.3.3 Eli Lilly and Company Neoantigen Vaccine Production, Revenue (2018-2022)
14.3.4 Strategic initiatives
14.4 BioNTech
14.4.1 BioNTech Company Profiles
14.4.2 BioNTech Product Introduction
14.4.3 BioNTech Neoantigen Vaccine Production, Revenue (2018-2022)
14.4.4 Strategic initiatives
14.5 Roche Holding AG
14.5.1 Roche Holding AG Company Profiles
14.5.2 Roche Holding AG Product Introduction
14.5.3 Roche Holding AG Neoantigen Vaccine Production, Revenue (2018-2022)
14.5.4 Strategic initiatives
14.6 OSE Immunotherapeutics
14.6.1 OSE Immunotherapeutics Company Profiles
14.6.2 OSE Immunotherapeutics Product Introduction
14.6.3 OSE Immunotherapeutics Neoantigen Vaccine Production, Revenue (2018-2022)
14.6.4 Strategic initiatives
14.7 Gritstone Bio
14.7.1 Gritstone Bio Company Profiles
14.7.2 Gritstone Bio Product Introduction
14.7.3 Gritstone Bio Neoantigen Vaccine Production, Revenue (2018-2022)
14.7.4 Strategic initiatives
14.8 Moderna
14.8.1 Moderna Company Profiles
14.8.2 Moderna Product Introduction
14.8.3 Moderna Neoantigen Vaccine Production, Revenue (2018-2022)
14.8.4 Strategic initiatives
14.9 Avidea Technologies
14.9.1 Avidea Technologies Company Profiles
14.9.2 Avidea Technologies Product Introduction
14.9.3 Avidea Technologies Neoantigen Vaccine Production, Revenue (2018-2022)
14.9.4 Strategic initiatives
14.10 Vaccibody AS
14.10.1 Vaccibody AS Company Profiles
14.10.2 Vaccibody AS Product Introduction
14.10.3 Vaccibody AS Neoantigen Vaccine Production, Revenue (2018-2022)
14.10.4 Strategic initiatives
14.11 Agenus Inc
14.12 Novogene
14.13 ZIOPHARM Oncology
14.14 ISA Pharmaceuticals
14.15 BrightPath Biotherapeutics
14.16 Vaximm AG
14.17 Medigene AG
14.18 Genocea Biosciences Inc
14.19 Advaxis
14.20 Nouscom
15. Conclusion
16. Methodology and Data Source

List of Figure

List of Tables and Figures

Figure 1. Total Demand by Application of Neoantigen Vaccine Industry (Volume)
Figure 2. Neoantigen Vaccine Production & Demand by Regions in 2022
Figure 3. Regional Market Share in Terms of Revenue (2022&2027)
Figure 4. The Top 10 and 5 Players Market Share by Neoantigen Vaccine Revenue in 2022
Figure 5. US Neoantigen Vaccine Production, Demand (2018-2028)
Figure 6. Production Breakdown by Type (%)
Figure 7. Demand Breakdown by Type (%)
Figure 8. Demand Breakdown by Application (%)
Figure 9. Revenue Breakdown by Type (%)
Figure 10. Revenue Breakdown by Application (%)
Figure 11. Europe Neoantigen Vaccine Production, Demand (2018-2028)
Figure 12. Production Breakdown by Type (%)
Figure 13. Demand Breakdown by Type (%)
Figure 14. Demand Breakdown by Application (%)
Figure 15. Revenue Breakdown by Type (%)
Figure 16. Revenue Breakdown by Application (%)
Figure 17. China Neoantigen Vaccine Production, Demand (2018-2028)
Figure 18. Production Breakdown by Type (%)
Figure 19. Demand Breakdown by Type (%)
Figure 20. Demand Breakdown by Application (%)
Figure 21. Current and Estimated Revenue Breakdown by Type
Figure 22. Revenue Breakdown by Type (%)
Figure 23. Revenue Breakdown by Application (%)
Figure 24. Japan Neoantigen Vaccine Production, Demand (2018-2028)
Figure 25. Production Breakdown by Type (%)
Figure 26. Demand Breakdown by Type (%)
Figure 27. Demand Breakdown by Application (%)
Figure 28. Revenue Breakdown by Type (%)
Figure 29. Revenue Breakdown by Application (%)
Figure 30. India Neoantigen Vaccine Production, Demand (2018-2028)
Figure 31. Production Breakdown by Type (%)
Figure 32. Demand Breakdown by Type (%)
Figure 33. Demand Breakdown by Application (%)
Figure 34. Revenue Breakdown by Type (%)
Figure 35. Revenue Breakdown by Application (%)
Figure 36. Korea Neoantigen Vaccine Production, Demand (2018-2028)
Figure 37. Production Breakdown by Type (%)
Figure 38. Demand Breakdown by Type (%)
Figure 39. Demand Breakdown by Application (%)
Figure 40. Revenue Breakdown by Type (%)
Figure 41. Revenue Breakdown by Application (%)
Figure 42. Southeast Asia Neoantigen Vaccine Production, Demand (2018-2028)
Figure 43. Current and Estimated Production Breakdown by Type (2018-2028)
Figure 44. Production Breakdown by Type (%)
Figure 45. Demand Breakdown by Type (%)
Figure 46. Revenue Breakdown by Type (%)
Figure 47. Revenue Breakdown by Application (%)
Figure 48. Industrial Chain
Table 1. Top Manufacturers and Market Segmentation
Table 2. Product Introduction, Application, Picture
Table 3. Neoantigen Vaccine Revenue, by Type (Million USD) (2018-2028)
Table 4. Neoantigen Vaccine Production, by Type (K Unit) (2018-2028)
Table 5. Neoantigen Vaccine Demand (K Unit) by Application (2018-2028)
Table 6. Neoantigen Vaccine Demand (Million USD) by Application (2018-2028)
Table 7. The Major Downstream Company in China
Table 8. Regional Market Share in Terms of Production & Demand (2022)
Table 9. Regional Market Share in Terms of Revenue (2022&2027)
Table 10. Ranking of Global Top Neoantigen Vaccine Companies by Revenue, Concentration Ratio in 2022
Table 11. Mergers & Acquisitions, Expansion Plans
Table 12. US Neoantigen Vaccine Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 13. Current and Estimated Production Breakdown by Type (2018-2028)
Table 14. Current and Estimated Demand Breakdown by Type (2018-2028)
Table 15. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 16. Current and Estimated Revenue Breakdown by Type
Table 17. Current and Estimated Revenue Breakdown by Application
Table 18. Europe Neoantigen Vaccine Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 19. Current and Estimated Production Breakdown by Type (2018-2028)
Table 20. Current and Estimated Demand Breakdown by Type (2018-2028)
Table 21. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 22. Current and Estimated Revenue Breakdown by Type
Table 23. Current and Estimated Revenue Breakdown by Application
Table 24. China Neoantigen Vaccine Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 25. Table Current and Estimated Production Breakdown by Type
Table 26. Current and Estimated Demand Breakdown by Type
Table 27. Current and Estimated Demand Breakdown by Application
Table 28. Current and Estimated Revenue Breakdown by Application
Table 29. Japan Neoantigen Vaccine Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 30. Current and Estimated Production Breakdown by Type (2018-2028)
Table 31. Current and Estimated Demand Breakdown by Type (2018-2028)
Table 32. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 33. Current and Estimated Revenue Breakdown by Type
Table 34. Current and Estimated Revenue Breakdown by Application
Table 35. India Neoantigen Vaccine Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 36. Current and Estimated Production Breakdown by Type (2018-2028)
Table 37. Current and Estimated Demand Breakdown by Type (2018-2028)
Table 38. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 39. Current and Estimated Revenue Breakdown by Type
Table 40. Current and Estimated Revenue Breakdown by Application
Table 41. Korea Neoantigen Vaccine Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 42. Current and Estimated Production Breakdown by Type (2018-2028)
Table 43. Current and Estimated Demand Breakdown by Type (2018-2028)
Table 44. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 45. Current and Estimated Revenue Breakdown by Type
Table 46. Current and Estimated Revenue Breakdown by Application
Table 47. Southeast Asia Neoantigen Vaccine Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 48. Table Current and Estimated Demand Breakdown by Type (2018-2028)
Table 49. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 50. Current and Estimated Revenue Breakdown by Type
Table 51. Current and Estimated Revenue Breakdown by Application
Table 52. Market Price (USD/Unit) for Each Type of Neoantigen Vaccine in US (2018-2022)
Table 53. Market Price (USD/Unit) for Each Type of Neoantigen Vaccine in Europe (2018-2022)
Table 54. Market Price (USD/Unit) for Each Type of Neoantigen Vaccine in China (2018-2022)
Table 55. Market Price (USD/Unit) for Each Type of Neoantigen Vaccine in Japan (2018-2022)
Table 56. Market Price (USD/Unit) for Each Type of Neoantigen Vaccine in India (2018-2022)
Table 57. Market Price (USD/Unit) for Each Type of Neoantigen Vaccine in Korea (2018-2022)
Table 58. Market Price (USD/Unit) for Each Type of Neoantigen Vaccine in Southeast Asia (2018-2022)
Table 59. Key Downstream Customer in Each Application Field
Table 60. Pfizer Profiles
Table 61. Pfizer Neoantigen Vaccine Product Introduction
Table 62. Pfizer Neoantigen Vaccine Production (Unit), Revenue (Million USD) (2018-2022)
Table 63. Pfizer Strategic initiatives
Table 64. Merck & Co Inc Profiles
Table 65. Merck & Co Inc Neoantigen Vaccine Product Introduction
Table 66. Merck & Co Inc Neoantigen Vaccine Production (Unit), Revenue (Million USD) (2018-2022)
Table 67. Merck & Co Inc Strategic initiatives
Table 68. Eli Lilly and Company Profiles
Table 69. Eli Lilly and Company Neoantigen Vaccine Product Introduction
Table 70. Eli Lilly and Company Neoantigen Vaccine Production (Unit), Revenue (Million USD) (2018-2022)
Table 71. Eli Lilly and Company Strategic initiatives
Table 72. BioNTech Profiles
Table 73. BioNTech Neoantigen Vaccine Product Introduction
Table 74. BioNTech Neoantigen Vaccine Production (Unit), Revenue (Million USD) (2018-2022)
Table 75. BioNTech Strategic initiatives
Table 76. Roche Holding AG Profiles
Table 77. Roche Holding AG Neoantigen Vaccine Product Introduction
Table 78. Roche Holding AG Neoantigen Vaccine Production (Unit), Revenue (Million USD) (2018-2022)
Table 79. Roche Holding AG Strategic initiatives
Table 80. OSE Immunotherapeutics Profiles
Table 81. OSE Immunotherapeutics Neoantigen Vaccine Product Introduction
Table 82. OSE Immunotherapeutics Neoantigen Vaccine Production (Unit), Revenue (Million USD) (2018-2022)
Table 83. OSE Immunotherapeutics Strategic initiatives
Table 84. Gritstone Bio Profiles
Table 85. Gritstone Bio Neoantigen Vaccine Product Introduction
Table 86. Gritstone Bio Neoantigen Vaccine Production (Unit), Revenue (Million USD) (2018-2022)
Table 87. Gritstone Bio Strategic initiatives
Table 88. Moderna Profiles
Table 89. Moderna Neoantigen Vaccine Product Introduction
Table 90. Moderna Neoantigen Vaccine Production (Unit), Revenue (Million USD) (2018-2022)
Table 91. Moderna Strategic initiatives
Table 92. Avidea Technologies Profiles
Table 93. Avidea Technologies Neoantigen Vaccine Product Introduction
Table 94. Avidea Technologies Neoantigen Vaccine Production (Unit), Revenue (Million USD) (2018-2022)
Table 95. Avidea Technologies Strategic initiatives
Table 97. Vaccibody AS Profiles
Table 98. Vaccibody AS Neoantigen Vaccine Product Introduction
Table 99. Vaccibody AS Neoantigen Vaccine Production (Unit), Revenue (Million USD) (2018-2022)
Table 100. Vaccibody AS Strategic initiatives
Table 101. Agenus Inc Profiles
Table 102. Agenus Inc Neoantigen Vaccine Product Introduction
Table 103. Agenus Inc Neoantigen Vaccine Production (Unit), Revenue (Million USD) (2018-2022)
Table 104. Agenus Inc Strategic initiatives
Table 105. Novogene Profiles
Table 106. Novogene Neoantigen Vaccine Product Introduction
Table 107. Novogene Neoantigen Vaccine Production (Unit), Revenue (Million USD) (2018-2022)
Table 108. Novogene Strategic initiatives
Table 109. ZIOPHARM Oncology Profiles
Table 110. ZIOPHARM Oncology Neoantigen Vaccine Product Introduction
Table 111. ZIOPHARM Oncology Neoantigen Vaccine Production (Unit), Revenue (Million USD) (2018-2022)
Table 112. ZIOPHARM Oncology Strategic initiatives
Table 113. ISA Pharmaceuticals Profiles
Table 114. ISA Pharmaceuticals Neoantigen Vaccine Product Introduction
Table 115. ISA Pharmaceuticals Neoantigen Vaccine Production (Unit), Revenue (Million USD) (2018-2022)
Table 116. ISA Pharmaceuticals Strategic initiatives
Table 117. BrightPath Biotherapeutics Profiles
Table 118. BrightPath Biotherapeutics Neoantigen Vaccine Product Introduction
Table 119. BrightPath Biotherapeutics Neoantigen Vaccine Production (Unit), Revenue (Million USD) (2018-2022)
Table 120. BrightPath Biotherapeutics Strategic initiatives
Table 121. Vaximm AG Profiles
Table 122. Vaximm AG Neoantigen Vaccine Product Introduction
Table 123. Vaximm AG Neoantigen Vaccine Production (Unit), Revenue (Million USD) (2018-2022)
Table 124. Vaximm AG Strategic initiatives
Table 125. Medigene AG Profiles
Table 126. Medigene AG Neoantigen Vaccine Product Introduction
Table 127. Medigene AG Neoantigen Vaccine Production (Unit), Revenue (Million USD) (2018-2022)
Table 128. Medigene AG Strategic initiatives
Table 129. Genocea Biosciences Inc Profiles
Table 130. Genocea Biosciences Inc Neoantigen Vaccine Product Introduction
Table 131. Genocea Biosciences Inc Neoantigen Vaccine Production (Unit), Revenue (Million USD) (2018-2022)
Table 132. Genocea Biosciences Inc Strategic initiatives
Table 133. Advaxis Profiles
Table 134. Advaxis Neoantigen Vaccine Product Introduction
Table 135. Advaxis Neoantigen Vaccine Production (Unit), Revenue (Million USD) (2018-2022)
Table 136. Advaxis Strategic initiatives
Table 137. Nouscom Profiles
Table 138. Nouscom Neoantigen Vaccine Product Introduction
Table 139. Nouscom Neoantigen Vaccine Production (Unit), Revenue (Million USD) (2018-2022)
Table 140. Nouscom Strategic initiatives